Landun Technology: Plans to acquire controlling stake in CRO company Junke Zhengyuan, with a total valuation of 1 billion yuan.

Zhongfu Technology announced that its wholly-owned subsidiary Dingfu Pharmaceutical intends to sign a "Framework Agreement for Equity Transfer" with Shanghai Jinpan and Siguang Hengsheng to plan the acquisition of the controlling rights of the national-level specialized and new "little giant" enterprise Junke Zhengyuan and its integrated CRO assets. The overall estimated value of the target equity is 1 billion yuan. After the completion of the transaction, the target company will be included in the company's consolidated financial statements. According to the agreement, Dingfu Pharmaceutical must pay no more than 30 million yuan as a purchase intention fee. In terms of performance commitment, it is expected that the non-deductible net profit of Junke Zhengyuan from 2026 to 2028 will be no less than 66 million yuan, 77 million yuan, and 88 million yuan respectively. This transaction does not constitute a related party transaction or a major asset restructuring, and the final plan is subject to audit evaluation and approval, with uncertainties remaining.